3

Blood Collection

Interview & Tests

2

Registration

CRITERIA CHARACTERISTICS General Appearance No presence of excessive anxiety, drug or alcohol influence or nervousness Age Body Weight Pulse Rate Blood Pressure Temperature Between 16-65 years old (parental consents is required under 18 y/o) At least 50 kg (500 ml blood unit) At least 45 kg (250 ml blood unit) 50 100 beats/minute (regular rhythm) Systolic: 90-160 mm Hg Diastolic: 60-100 mm Hg 37 degrees Celsius 98.6 degrees Fahrenheit

CRITERIA Skin HEENT

CHARACTERISTICS Deferral : Evidence skin lesions (puncture arks) O served donor s facial expression, visual & hearing a ility, and physiology of the nose, outh & tongue, etc. [sy etry, size, shape, asses, involuntary ove ents, lesions, allergies] Per anent deferral if severe heart and lung disease is present 2 g/L ( 2. g/dL) Male: - 9 Fe ale: 3 - 9

Heart & Lungs He oglobin He atocrit

CONDITION Previ us D nati n Pregnant men

DURATION 3 onths or longer interval fro previous donation of 5 l 9 onths after child irth 3 onths after weaning (whichever is longer) 1 onths after operation or transfusion

Maj r Operati n inclu ing: a. Dental Surgery . l transfusi n inclu e a ministrati n f immun gl ulins Acute Fe rile Illness Malaria ( iagn se

-3 weeks after fe rile episode or until full recovery r treate ) 3 years after cessation of S/S of alaria/treat ent of alaria

CONDITION Past exp sure t a cl se use l c ntact wit epatitis Past exp sure t un ygienic skin, piercing, tatt ing, ear l ing, nee le puncture, etc. Recent alc f r alc

DURATION 1 year after exposure

1 year after exposure

l intake (p sitive 1 hours after last alcohol intake lic reat ) fter skin have co pletely healed 1 week efore enstruation

Skin lesi ns at venipuncture site Menstruati n (f r females nly)

TREATMENT Live attenuate vaccines

DURATION

Category 1: Measles (ru e la), 2 weeks after vaccination Oral p li , Mumps. Yell w fever vaccines, CG Category 2: German measles (ru ella) vaccine Category 3: Ra ies vaccines Kille vaccines an t x i s (DPT an DT, p li injecta le, H V, C lera, Typ i an paratyp i typ us an influenza vaccines 1 1 onth after vaccination onth after vaccination

May donate any ti e if without vaccine associate sy pto s like fever

TREATMENT Anti i tics t er t an anti-T rugs Anti-T rugs

DURATION 5 days after the last dose

Until TB is co pletely cured 5 days after co pletion of treat ent 1 day after the last dose ( ut lood is la eled NOT FOR THE PREP R TION OF PL TELETS) While on treat ent

Anti-Fungal rugs

Allergic rugs suc an penicillin an aspirin, is tretin in, etretinat Oral C rtic ster i s

 

    

    

DISEASE

TEST

PRINCIPLE

DILUENT

ANALYTE

CONJUGATED PAD

TEST AND

Pf HRP-2

Anti-HRP-2 Ab colloidal goild conjugate Anti-P. vivax colloidal gold conjugate Anti-Pan specific pLDH Ab colloidal gold conjugate Protein A colloidal gold conjugate

Monoclonal Anti-Pf HRP-2 Ab Monoclonal Anti-P. vivax specific pLDH Ab Monoclonal AntiPan specific pLDH Ab Reco binant HCV capture Ag Anti-rabbit Abs

Malaria

Rapid test for Malaria

Two-site Sandwich immunoassay immunochromatography

Tris Buffer

P. vivax specific pLDH

Anti-rabbit Abs

Pan specific pLDH One step HCV test

HCV

Immunochomatography

Tris Buffer

Anti-HCV Abs

Immunochomatography

Tris Buffer







nti-gp 1 nti-p 24 nti-gp 36

      

  

Rapid Test for detection HIV/AIDS of s to HIV 1&2

Reco inant HIV gs colloidal gold conjugate

Reco inant HIV-1 capture g (gp41 & p24) Reco inant HIV-2 capture g (gp36)

nti-ra it s

VDRL

Tris Buffer

 

One step Syphilis antiTP

Solid phase immunochomatography assay

IgG, IgM, Ig against T. palladiu

Reco inant T. palladiu g

Goat ntitrepone al seru

Reco inant T. palladiu g colloidal gold conjugate

H sAg

Immunochormatography

H s g

One step H s g test

Mouse onoclonal Mouse onoclonal anti-H s colloidal anti-H s capture gold conjugate

CONTROL PAD

nti-ra it s